Publications

Found 106 results
Type [ Year(Asc)]
2016
ML Maeder, and CA Gersbach. "Genome-editing Technologies for Gene and Cell Therapy." Molecular Therapy 24, no. 3 (2016): 430-446.
CE Nelson, CH Hakim, DG Ousterout, PI Thakore, EA Moreb, RM Castellano Rivera, S Madhavan, X Pan, FA Ran, WX Yan et al. "In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy." Science 351, no. 6271 (2016): 403-407.
DJ Landau, ED Brooks, P Perez-Pinera, H Amarasekara, A Mefferd, S Li, A Bird, CA Gersbach, and DD Koeberl. "In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA." Molecular Therapy 24, no. 4 (2016): 697-706.
BE Housden, M Muhar, M Gemberling, CA Gersbach, DYR Stainier, G Seydoux, SE Mohr, J Zuber, and N Perrimon. "Loss-of-function genetic tools for animal models: cross-species and cross-platform differences." Nature Reviews Genetics 18, no. 1 (2016): 24-40.
PY Hwang, L Jing, J Chen, FL Lim, R Tang, H Choi, KM Cheung, MV Risbud, CA Gersbach, F Guilak et al. "N-cadherin is Key to Expression of the Nucleus Pulposus Cell Phenotype under Selective Substrate Culture Conditions." Scientific Reports 6 (2016).
EA Josephs, DD Kocak, CJ Fitzgibbon, J McMenemy, CA Gersbach, and PE Marszalek. "Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage." Nucleic Acids Research 44, no. 5 (2016).
JB Black, AF Adler, HG Wang, AM D'Ippolito, HA Hutchinson, TE Reddy, GS Pitt, KW Leong, and CA Gersbach. "Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells." Cell Stem Cell 19, no. 3 (2016): 406-414.
2015
J Black, A Adler, H Hutchinson, H Wang, G Pitt, K Leong, and C Gersbach. "59. Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
KA Glass, AK Ross, SA Compton, CA Gersbach, FT Moutos, BT Estes, and F Guilak. "Anatomically-Shaped Tissue-Engineered Cartilage with Tunable and Inducible Anti-Inflammatory Capabilities." In Tissue Engineering, Part A, S330. Vol. 21. 2015.
DG Ousterout, AM Kabadi, PI Thakore, P Perez-Pinera, MT Brown, WH Majoros, TE Reddy, and CA Gersbach. "Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular Therapy 23, no. 3 (2015): 523-532.
DG Ousterout, AM Kabadi, PI Thakore, P Perez-Pinera, MT Brown, WH Majoros, TE Reddy, and CA Gersbach. "Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular Therapy 23, no. 3 (2015): 523-532.
N Farhang, JM Brunger, JD Stover, PI Thakore, BD Lawrence, F Guilak, CA Gersbach, LA Setton, and RD Bowles. "CRISPRi Immunomodulation for Tissue Engineering/Stem Cell Therapies Targeting Intervertebral Disc Degeneration." In Tissue Engineering, Part A, S170. Vol. 21. 2015.
IB Hilton, and CA Gersbach. "Enabling functional genomics with genome engineering." Genome research 25, no. 10 (2015): 1442-1455.
AM Kabadi, PI Thakore, CM Vockley, DG Ousterout, TM Gibson, F Guilak, TE Reddy, and CA Gersbach. "Enhanced MyoD-Induced Transdifferentiation to a Myogenic Lineage by Fusion to a Potent Transactivation Domain." ACS Synthetic Biology 4, no. 6 (2015): 689-699.
IB Hilton, AM D'Ippolito, CM Vockley, PI Thakore, GE Crawford, TE Reddy, and CA Gersbach. "Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers." Nature Biotechnology 33, no. 5 (2015): 510-517.
JA Doudna, and CA Gersbach. "Genome editing: the end of the beginning." Genome Biology 16, no. 1 (2015).
LR Polstein, P Perez-Pinera, DD Kocak, CM Vockley, P Bledsoe, L Song, A Safi, GE Crawford, TE Reddy, and CA Gersbach. "Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators." Genome research 25, no. 8 (2015): 1158-1169.
PI Thakore, AM D'Ippolito, L Song, A Safi, NK Shivakumar, AM Kabadi, TE Reddy, GE Crawford, and CA Gersbach. "Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements." Nature Methods 12, no. 12 (2015): 1143-1149.
BO Diekman, PI Thakore, SK O'Connor, VP Willard, JM Brunger, N Christoforou, KW Leong, CA Gersbach, and F Guilak. "Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells." Tissue Engineering, Part A 21, no. 7-8 (2015): 1261-1274.
LR Polstein, and CA Gersbach. "A light-inducible CRISPR-Cas9 system for control of endogenous gene activation." Nature Chemical Biology 11, no. 3 (2015): 198-200.
DG Ousterout, AM Kabadi, PI Thakore, WH Majoros, TE Reddy, and CA Gersbach. "Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy." Nature Communications 6 (2015): 6244-.
J Black, A Adler, H Hutchinson, H Wang, G Pitt, K Leong, and C Gersbach. "Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
CL Frank, F Liu, R Wijayatunge, L Song, MT Biegler, MG Yang, CM Vockley, A Safi, CA Gersbach, GE Crawford et al. "Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum." Nature Neuroscience 18, no. 5 (2015): 647-656.
TM Gibson, and CA Gersbach. "Single-molecule analysis of myocyte differentiation reveals bimodal lineage commitment." Integrative Biology 7, no. 6 (2015): 663-671.
EA Josephs, DD Kocak, CJ Fitzgibbon, J McMenemy, CA Gersbach, and PE Marszalek. "Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage." Nucleic Acids Research 43, no. 18 (2015): 8924-8941.

Pages